
<!-- saved from url=(0086)https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?ver=EN&numEc=034-20 -->
<html class="js-focus-visible" data-js-focus-visible=""><head><meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<title>ENSAYOS CLINICOS - INSTITUTO NACIONAL DE SALUD</title>

<link href="./Ref 7_files/estilos_trans1.css" rel="stylesheet" type="text/css">

<style type="text/css">
@font-face {
  font-weight: 400;
  font-style:  normal;
  font-family: 'Circular-Loom';

  src: url('https://cdn.loom.com/assets/fonts/circular/CircularXXWeb-Book-cd7d2bcec649b1243839a15d5eb8f0a3.woff2') format('woff2');
}

@font-face {
  font-weight: 500;
  font-style:  normal;
  font-family: 'Circular-Loom';

  src: url('https://cdn.loom.com/assets/fonts/circular/CircularXXWeb-Medium-d74eac43c78bd5852478998ce63dceb3.woff2') format('woff2');
}

@font-face {
  font-weight: 700;
  font-style:  normal;
  font-family: 'Circular-Loom';

  src: url('https://cdn.loom.com/assets/fonts/circular/CircularXXWeb-Bold-83b8ceaf77f49c7cffa44107561909e4.woff2') format('woff2');
}

@font-face {
  font-weight: 900;
  font-style:  normal;
  font-family: 'Circular-Loom';

  src: url('https://cdn.loom.com/assets/fonts/circular/CircularXXWeb-Black-bf067ecb8aa777ceb6df7d72226febca.woff2') format('woff2');
}</style></head>

<body bgcolor="#FFFFFF" text="#000000" topmargin="0" leftmargin="0" marginwidth="0" marginheight="0"> 
 
  <table cellpadding="0" cellspacing="0" border="0" width="100%" height="100%" bordercolor="#003366" bgcolor="#EEEEEE" align="center">
 <tbody><tr>
<td colspan="2" valign="top" width="100%" height="16" class="TdAzulCuerpoBoldPq">
<style type="text/css">
<!--
.Estilo1 {
	color: #FFFFFF;
	font-weight: bold;
	font-family: Arial;
	text-align:center;
	
}
-->
</style>

<table cellpadding="0" cellspacing="0" border="0" width="100%">
							<tbody><tr> <td width="960" height="30" align="center" valign="middle"><img src="./Ref 7_files/RPECEN.jpg" width="646" height="75" border="0">
</td>
 </tr>
</tbody></table>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
 <table border="0" cellspacing="2" cellpadding="2" align="CENTER" width="100%">
  
 
 <tbody><tr><td valign="top" align="center">
  <!-- Artificio para netscape -->
  <table border="0" cellpadding="2" cellspacing="0" bordercolor="#D5EAFF" width="100%">
 
	<tbody><tr>
	<td>
	 <table border="0" cellpadding="0" cellspacing="0" bordercolor="#D5EAFF" width="100%">
    <tbody><tr><td><a href="https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?ver=SP&amp;numEc=034-20">Versión en Español</a>
	</td></tr>
	<tr><td align="center"><table border="1" cellpadding="0" cellspacing="0" width="98%" bordercolor="#0080C0">
	 <tbody><tr>
	<td align="center" colspan="2">
	
<table width="100%" border="0" cellpadding="4" cellspacing="0" bgcolor="#ffffff" bordercolor="ffffff">

	<tbody><tr>
	  <td class="TdBlancoCuerpoBold" align="center" bgcolor="#0080C0">DATA SHEET </td>
	</tr>
	
	<tr>
	<td width="100%" align="center">
	<table width="100%" border="1" cellpadding="0" cellspacing="0" bordercolor="#FFFFFF" bgcolor="#FFFFFF">
	
	<tbody><tr>
	<td bgcolor="#6AB5FF" class="TdBlancoCuerpoBoldPq" colspan="4" height="35">CLINICAL TRIAL REGISTRATION (EC) </td>
	</tr>
	<tr>
	  <td width="25%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top"> EC INS No: </td>
	   <td class="TdNegroCuerposPq" valign="top" colspan="3">&nbsp;PER-034-20</td>
	  </tr>

	
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
	  <tr>
	  <td class="TdBlancoCuerpoBoldPq" bgcolor="#6AB5FF" colspan="4" height="25"> 1. ORGANIZATION / APPLICANTE INSTITUTION </td>
	</tr>
	
	<tr>
	<td valign="top" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq"> Name of Organization / Institution:</td>
	<td class="TdNegroCuerposPq">   UNIVERSIDAD PERUANA CAYETANO HEREDIA &nbsp;</td>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Type of Organization / Institution  : </td>
     <td class="TdNegroCuerposPq">
	  Universidad&nbsp;
	 </td></tr>
	
	 <tr>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Legal Domicile : </td>
     <td colspan="3" class="TdNegroCuerposPq">Av. Honorio Delgado 430&nbsp;	 </td>
	 </tr>
	  <tr>
     <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">District:</td>
     <td class="TdNegroCuerposPq">San Martin de Porres&nbsp;	 </td>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq"> Province:	 </td>
     <td class="TdNegroCuerposPq">Lima&nbsp;	 </td>
	 </tr>
	<tr>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Departament:	 </td>
     <td colspan="3" class="TdNegroCuerposPq">Lima&nbsp;	 </td>
	 </tr> <tr>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Single Taxpayer No :	 </td>
     <td colspan="3" class="TdNegroCuerposPq">20110768151&nbsp;	 </td>
	 </tr>
	 <tr>
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq"> Telephone:	 </td>
     <td class="TdNegroCuerposPq">3190000&nbsp;	 </td>
	
     <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">&nbsp;Fax:	 </td><td class="TdNegroCuerposPq">&nbsp;

	 </td>
	 </tr>
	
	 
	
	
      </tbody></table></td>
	</tr>
	
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
	
	
	
	
	
	
	<tr>
	<td width="100%" align="center">
	<table width="100%" border="1" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF" bordercolor="#FFFFFF">
	
		<tbody><tr>
	<td bgcolor="#6AB5FF" class="TdBlancoCuerpoBoldPq" colspan="4" height="25">2. CLINICAL TRIAL GENERAL INFORMATION </td>
	</tr>
        <tr>
       
		
	<td colspan="4" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">Scientific title: </td>
		  </tr>
		
		<tr><td class="TdNegroCuerposPq" colspan="4">
		

		  <font style="text-decoration:underline">
RANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19 <br><br>
</font>
		
		
		<br>
</td></tr>
		 <tr>
          <td colspan="4" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">Public Title </td>
		  </tr>
		<tr><td class="TdNegroCuerposPq" colspan="4">
		

		  <font style="text-decoration:underline">
RANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19<br><br>
</font>
		
		
		
		<br>
</td></tr> <tr>
          <td colspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">Clinical Trial Registration Date  </td>   
          <td colspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">Most recent Clinical Trial Update </td>
		  </tr>
		  <tr>
          <td colspan="2" class="TdNegroCuerposPq" valign="top">17/07/2020 </td>   
          <td colspan="2" class="TdNegroCuerposPq" valign="top">&nbsp;</td>
		  </tr>
		
		<tr>
          <td colspan="4" valign="top" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Principal Sponsor : </td>
		  
        </tr>
		
		<tr class="TdNegroCuerposPq"><td colspan="2">1.-&nbsp;UNIVERSIDAD PERUANA CAYETANO HEREDIA</td>
		<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
          <td colspan="4" valign="top" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Secondary Sponsor : </td>
		  
        </tr>
		
		<tr><td colspan="4">&nbsp;</td></tr>
		
		<tr class="TdNegroCuerpoBoldPq">
     <td bgcolor="#E8E8F0" colspan="4">Funding Source </td>
   </tr>
   
   <tr class="TdNegroCuerposPq">
     <td colspan="4">1.-&nbsp;&nbsp;UNIVERSIDAD PERUANA CAYETANO HEREDIA</td>
   </tr>
   
		<tr>
		  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Executing Company / Institution / Other </td>  
		</tr>
		
	
		<tr class="TdNegroCuerposPq"><td width="24%">-&nbsp;UNIVERSIDAD PERUANA CAYETANO HEREDIA </td><td width="24%">-&nbsp;</td>
	
		
		
	  <td class="TdNegroCuerposPq" colspan="2">Authorized with  &nbsp; 238-2020-OGITT-INS Date 17/07/2020</td></tr>
	
			
			<!--- Desiganción de Responsabilidades --> <tr bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">
      
        <td colspan="4">Responsabilities</td>
		
		
       </tr> 
	   
	   <tr class="TdNegroCuerposPq">
    
            <td colspan="4">
             &nbsp;</td>
      </tr> 
	  <tr class="TdNegroCuerposPq">
    
            <td colspan="1">&nbsp;</td>
            <td colspan="3">Others</td>
      </tr> 
	  
	   <tr class="TdNegroCuerposPq">
    
            <td colspan="4">
            UNIVERSIDAD PERUANA CAYETANO HEREDIA  &nbsp;</td>
      </tr> 
	  <tr class="TdNegroCuerposPq">
    
            <td colspan="1">&nbsp;</td>
            <td colspan="3">Inform to the OGITT of the NIH when the first subject is enrolled in Peru, and the end date of enrollment in the country.</td>
      </tr> 
	  
     <tr class="TdNegroCuerposPq">
    
          <td colspan="1">&nbsp;</td>  <td colspan="3">Submit progress reports to the National Health Institute during the execution of the Clinical Trial.</td>
      </tr>
	   
	  
     <tr class="TdNegroCuerposPq">
    
          <td colspan="1">&nbsp;</td>  <td colspan="3">Submit to the OGITT of the NIH the final reports as well as the results, conclusions, and publication of the clinical trial</td>
      </tr>
	   
	  
     <tr class="TdNegroCuerposPq">
    
          <td colspan="1">&nbsp;</td>  <td colspan="3">Notify to the OGITT of the NIH the adverse events and deviations as established in the Clinical Trials Regulation.</td>
      </tr>
	   
	  
     <tr class="TdNegroCuerposPq">
    
          <td colspan="1">&nbsp;</td>  <td colspan="3">Inform and describe the reasons for a suspension and cancellation of the clinical trial.</td>
      </tr>
	   
	  
     <tr class="TdNegroCuerposPq">
    
          <td colspan="1">&nbsp;</td>  <td colspan="3"> Provide the facilities for the inspection of the execution of the clinical trial by the staff of the General Office of Research and Technology Transfer (OGITT) of the National Institute of Health.</td>
      </tr>
	   
	  
   	<tr>
	  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%" rowspan="5">Study clinical phase: </td>
        <td width="24%" class="TdNegroCuerposPq" rowspan="5">II&nbsp;        </td>    
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Protocol Code </td>
        <td valign="top" class="TdNegroCuerposPq" width="26%">SAINT-PERÚ&nbsp;        </td>
	</tr>	
	
	
	<tr>
     <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Secondary ID(s) : </td>
     <td>&nbsp;</td></tr><tr>
  
     <td class="TdNegroCuerposPq" align="justify">WHO UTN:</td>
     <td class="TdNegroCuerposPq">NA      </td></tr><tr>
       <td class="TdNegroCuerposPq">

CLINICALTRIALS.GOV:</td>
       <td class="TdNegroCuerposPq">NA   </td></tr><tr><td class="TdNegroCuerposPq">
EUDRACT N°:</td><td class="TdNegroCuerposPq">NA </td>
   </tr>
	<tr>
	
         <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Study Design </td>
	</tr>	
	<tr>
	    <td class="TdNegroCuerposPq" colspan="4">This al is a triple-blind, randomized phase 2a ontrolled trial with two parallel groups to evaluate the efficacy of ivermectin in reducing nasal viral carriage at 7 days after treatment in SARS-CoV-2 infected patients. The study will recruit 68 patients (34 per group). Selected patients will be randomized to receive one (1) daily dose of 300 mcg/kg ivermectin or an equivalent placebo during three (3) consecutive days, and they will remain in the trial for a period of 21 days.. This study will take place in the Hospital Cayetano Heredia.&nbsp;</td>
	</tr>	
	<tr>
	  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%">Insurance policy due date </td>
        <td valign="top" class="TdNegroCuerposPq" width="24%">07/01/2021&nbsp;      </td>
       
         <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Assignation  method  </td>
		<td class="TdNegroCuerposPq" valign="top">
		<input type="radio" name="metodo_asignacion" value="1" class="TdNegroCuerpoBoldPq" checked="checked">
		Randomized&nbsp;<br>
		<input type="radio" name="metodo_asignacion" value="0" class="TdNegroCuerpoBoldPq">Non randomized&nbsp;</td>
	</tr>	<tr>
        <td height="8" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" colspan="2">Type of blinding </td>   
       
        <td height="8" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" colspan="2">Assignation</td>
	</tr><tr><td colspan="2" class="TdNegroCuerposPq" valign="top"><input type="radio" name="tipo_cegamiento" value="1" class="TdNegroCuerpoBoldPq">Simple&nbsp;<input type="radio" name="tipo_cegamiento" value="2" class="TdNegroCuerpoBoldPq">
        Double&nbsp;
        <input type="radio" name="tipo_cegamiento" value="3" class="TdNegroCuerpoBoldPq" checked="checked">
		Triple&nbsp;<br>
<input type="radio" name="tipo_cegamiento" value="4" class="TdNegroCuerpoBoldPq"> 
Open
</td>
		  <td valign="top" colspan="2" class="TdNegroCuerposPq">
		
		<input type="radio" name="asignacion" value="1" class="TdNegroCuerpoBoldPq">
		Single arm &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<input type="radio" name="asignacion" value="2" class="TdNegroCuerpoBoldPq" checked="checked">
		Parallel<br>
	<input type="radio" name="asignacion" value="3" class="TdNegroCuerpoBoldPq">
	Crossed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<input type="radio" name="asignacion" value="4" class="TdNegroCuerpoBoldPq">
	Factorial <br>
<input type="radio" name="asignacion" value="5" class="TdNegroCuerpoBoldPq">
Others:</td>
		</tr>
	<tr>
	
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Purpose </td>
	</tr>	
	<tr>
	
        <td class="TdNegroCuerposPq" colspan="4">To determine the efficacy of one (1) daily dose of ivermectin during three (3) consecutive days, administered to non-severe COVID-19 patients in the first 96 hours after symptoms onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day seven post-treatment. The efficacy of the drug-based strategy to reduce or block transmission involves treating during early phases of infection, when viral replication is yet limited.&nbsp;</td>
	</tr>	
		<tr class="TdNegroCuerpoBoldPq"> 
	  <td colspan="4" bgcolor="#E8E8F0">Research Product Information </td>
	</tr>		<tr class="TdNegroCuerpoBoldPq"> 
	  <td colspan="4" bgcolor="#E8E8F0" height="1">	  </td>
	</tr>	
	<tr class="TdNegroCuerpoBoldPq"> 
	  <td width="24%" bgcolor="#E8E8F0">Name of the product </td>
	  <td width="24%" bgcolor="#E8E8F0">Generic Name </td>
	  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Type of product </td>
	   <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">ATC </td>
	</tr>	
	
		<tr class="TdNegroCuerposPq"><td>IVERMECTINA  </td> <td>Ivermectina &nbsp;</td> <td width="26%">&nbsp;&nbsp;</td><td width="26%">&nbsp;&nbsp;P03       </td>
		</tr>
	
		
			<tr>
	
       
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Intervention(s) description: </td>
	</tr>	<tr>
	  <td valign="top" align="justify" colspan="4" class="TdNegroCuerpoBoldPq">
	  <table cellpadding="1" cellspacing="0" border="1" width="100%" bgcolor="#FFFFFF" bordercolor="#E8E8F0">
		

	
			<tbody><tr class="TdNegroCuerpoBoldPq"> 
	
	
	  <td width="19%" bgcolor="#E8E8F0">Group name </td>
	  <td width="13%" bgcolor="#E8E8F0">Type of group </td>
	  <td width="10%" bgcolor="#E8E8F0">N° of participants </td>
	  
	   <td width="58%" bgcolor="#E8E8F0">Intervention(s) description </td>
	</tr>	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF">
	 <td width="19%">IVERMECTIN</td><td class="TdNegroCuerpoxPq" width="13%">
		
		<input type="radio" name="tipo_grupoIaf1" value="1" class="TdNegroCuerpoBoldlPq" checked="checked">
	 Experimental<br>
			<input type="radio" name="tipo_grupoIaf1" value="2" class="TdNegroCuerpoBoldlPq"> Control</td><td width="10%">34&nbsp;</td><td width="58%">&nbsp;&nbsp;The participants will receive one (1) daily dose of 300 mcg/kg ivermectina for three (3) consecutive days. The Ivermectin presentation will be an oral drop solution.</td>
		</tr>
	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF">
	 <td width="19%">Ivermectin placebo</td><td class="TdNegroCuerpoxPq" width="13%">
		
		<input type="radio" name="tipo_grupoIaf2" value="1" class="TdNegroCuerpoBoldlPq">
	 Experimental<br>
			<input type="radio" name="tipo_grupoIaf2" value="2" class="TdNegroCuerpoBoldlPq" checked="checked"> Control</td><td width="10%">34&nbsp;</td><td width="58%">&nbsp;&nbsp;The participants will receive one (1) daily dose of an ivermectin placebo for three (3) consecutive days. The placebo presentation will be an oral drop solution undistinguishable </td>
		</tr>
	
		
		</tbody></table></td>
		</tr>	
		<tr>
	 
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Inclusion Criteria </td>
	</tr>	
	  
        <tr><td class="TdNegroCuerposPq" colspan="4">1. Patients with COVID-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours, 2. The patient must be elder than 18 years old. 3. Not previous administration of ivermectin before the study. 4. No known history of ivermectin allergy. 5. The patient can give his consent to take part in the study. 6. Current use of CYP 3A4 or P-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. Use of critical CYP3A4 substrate drugs such as warfarin.&nbsp;</td>
       
       
	</tr>	
	
		<tr>
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" colspan="4">Exclusion Criteria </td>
	</tr>	<tr>
	
	  

        <td class="TdNegroCuerposPq" colspan="4">1.	COVID-19 pneumonia
      	Diagnosed by the attending physician (oxygen saturation &lt; 95% or lung crackles)
2.	Positive pregnancy test for women of child bearing age
3.	Positive IgG against SARS-CoV-2 by rapid diagnostic test.
4.	Negative SARS-CoV-2 PCR from a nasopharyngeal swab.
&nbsp;</td>       
       
	</tr>	
			<tr>
    
        <td width="24%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq">Worldwide enrolment start date </td>
        <td class="TdNegroCuerposPq" colspan="3">&nbsp;</td> </tr><tr> 
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%">Enrolment start date in Peru (Initial) </td>
        <td valign="top" class="TdNegroCuerposPq" width="24%">
      09/07/2020&nbsp;          </td>  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Enrolment start date in Peru </td>
        <td valign="top" class="TdNegroCuerposPq" width="26%">
      29/08/2020&nbsp;          </td>
      </tr>  
	  <tr>
          <td height="8" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq"><span class="TdNegroCuerpoBoldlPq">Peru enrolment status </span></td> 
       
          <td valign="top" class="TdNegroCuerposPq"> 
		    <input type="radio" name="estado_ep" value="1">
            Without starting enrollment <br>
 <input type="radio" name="estado_ep" value="3">  
            Enrollment stopped			</td>
			<td valign="top" class="TdNegroCuerposPq" colspan="2"> 
              <input type="radio" name="estado_ep" value="2" checked="checked">
&nbsp; In enrollment <br>

            <input type="radio" name="estado_ep" value="4">  
            &nbsp; Enrollment closed&nbsp;    </td>
	  </tr> <tr>
    
        <td width="24%" bgcolor="#E8E8F0" rowspan="2" class="TdNegroCuerpoBoldPq">Clinical Trial Total Duration </td>
        <td class="TdNegroCuerposPq" rowspan="2">6&nbsp; months</td>  
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Medical Speciality </td>
        <td valign="top" class="TdNegroCuerposPq">
          INFECTOLOGY&nbsp;           </td>
      </tr>
        <tr>
      
		  <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Studied Condition (CIE-10 code) </td>
		  <td valign="top" class="TdNegroCuerposPq">-B342 Coronavirus infection, unspecified site
&nbsp;		</td>
      </tr>	
	
		<tr>        </tr> 
     <tr>
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" rowspan="2" width="24%">Number of subjects to be included in all the countries </td>
        <td valign="top" class="TdNegroCuerposPq" width="24%" rowspan="2">68&nbsp;
          <br></td>
       <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Number of subjects to be included in Peru (initial) </td>
     <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Number of subjects to be included in Peru (posterior) </td>
      </tr>
	  <tr>         <td valign="top" class="TdNegroCuerposPq" width="26%">68</td>
        <td valign="top" class="TdNegroCuerposPq" width="26%">    68       </td>
	  </tr>
		  <tr>
     <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%">Countries where the enrolment is conducted : </td>
     <td valign="top" class="TdNegroCuerposPq" colspan="3">
         <table cellpadding="0" cellspacing="1" border="0" width="100%">
           
           <tbody><tr>
             
             <td valign="top" class="TdNegroCuerposPq">- Peru</td>
             
         </tr></tbody></table>
       </td>
   </tr>
      <tr>
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%">Number of participants per gender (Initial)  </td> 
        <td valign="top" class="TdNegroCuerposPq" width="24%">Female: 
          0&nbsp;
          <br>
          Male
          : 
          0&nbsp;
          <br></td> 
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Number of participants per gender (Posterior)  </td>
        <td class="TdNegroCuerposPq">Female: 
          0&nbsp;
          <br>
          Male
          : 
          0</td>
      
      </tr>
		  
		   
	<tr>
	 <td class="TdNegroCuerpoBoldPq" width="24%" rowspan="10" bgcolor="#E8E8F0">Range of age of subjects to be included :</td>
     <td valign="top" class="TdNegroCuerposPq" width="24%"><span class="TdNegroCuerposPq">- Adults (18-64 years) </span>        </td> 
     <td class="TdNegroCuerposPq" valign="top" colspan="2"> <input type="radio" name="flgAdulto" value="1" checked="checked">  Yes &nbsp;
          <input type="radio" name="flgAdulto" value="0">No</td></tr>
		<tr>
		  <td class="TdNegroCuerposPq" valign="top">
  - Elderly (&gt;= 65 years)		  </td> <td class="TdNegroCuerposPq" valign="top" colspan="2">
		 <input type="radio" name="flgAdultoM" value="1" checked="checked">
		  Yes &nbsp;
		  <input type="radio" name="flgAdultoM" value="0">No</td></tr>
 <tr> <td class="TdNegroCuerposPq" valign="top">
  - Under 18 years  </td> <td class="TdNegroCuerposPq" valign="top" colspan="2"> <input type="radio" name="flgMenores" value="1" onclick=" 
		 form1.flgInUtero[0].disabled=false;
		 form1.flgRNPrematuro[0].disabled=false;
		form1.flgRN[0].disabled=false;
		 form1.flgLactPreEscolar[0].disabled=false;
		 form1.flgNinio[0].disabled=false;
		 form1.flgAdolescente[0].disabled=false;
	   ">
 Yes &nbsp;
 <input type="radio" name="flgMenores" value="0" checked="checked" onclick=" 
		 form1.flgInUtero[1].checked=checked;
		 form1.flgInUtero[0].disabled=true;
		  form1.flgRNPrematuro[1].checked=checked;
		 form1.flgRNPrematuro[0].disabled=true;
		  form1.flgRN[1].checked=checked;
		 form1.flgRN[0].disabled=true;
		  form1.flgLactPreEscolar[1].checked=checked;
		 form1.flgLactPreEscolar[0].disabled=true;
		  form1.flgNinio[1].checked=checked;
		 form1.flgNinio[0].disabled=true;
		  form1.flgAdolescente[1].checked=checked;
		 form1.flgAdolescente[0].disabled=true;
	   ">
 No </td></tr><tr>
<td class="TdNegroCuerposPq" valign="top">&nbsp; </td>
<td class="TdNegroCuerposPq" valign="top" colspan="2">
 If yes, specify:</td></tr><tr><td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td> <td class="TdNegroCuerposPq" valign="top">
 - In Utero </td> 
   <td class="TdNegroCuerposPq" valign="top">
 
 <input type="radio" name="flgInUtero" value="1">
 Yes&nbsp;
 <input type="radio" name="flgInUtero" value="0" checked="checked">No</td></tr>
 <tr><td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td> <td class="TdNegroCuerposPq" valign="top">
 - Preterm newborn  infants  (up to gestational age  &lt; 37 weeks)</td> 
 <td class="TdNegroCuerposPq" valign="top">
 
 <input type="radio" name="flgRNPrematuro" value="1">
 Yes&nbsp;
 <input type="radio" name="flgRNPrematuro" value="0" checked="checked">No</td></tr>
 <tr> <td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td><td class="TdNegroCuerposPq" valign="top">
- Newborns (0-27 días)
 </td>  
 <td class="TdNegroCuerposPq" valign="top"> <input type="radio" name="flgRN" value="1">
   Yes&nbsp;
   <input type="radio" name="flgRN" value="0" checked="checked">No</td>   
 </tr> 
  <tr> <td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td><td class="TdNegroCuerposPq" valign="top">
- Infants and toddlers  (28 days-23 months) </td>  
  <td class="TdNegroCuerposPq" valign="top">
 <input type="radio" name="flgLactPreEscolar" value="1">
 Yes&nbsp;
 <input type="radio" name="flgLactPreEscolar" value="0" checked="checked">No</td>   
  </tr>  <tr><td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td> <td class="TdNegroCuerposPq" valign="top">
- Children  (2 - 11 years) </td>  
    <td class="TdNegroCuerposPq" valign="top">

<input type="radio" name="flgNinio" value="1">
Yes&nbsp;
<input type="radio" name="flgNinio" value="0" checked="checked">No</td>   
  </tr>  <tr>  <td class="TdNegroCuerposPq" valign="top">&nbsp;
 </td><td class="TdNegroCuerposPq" valign="top">
- Adolescents  (12 - 17 years) </td>    
    <td class="TdNegroCuerposPq" valign="top">

<input type="radio" name="flgAdolescente" value="1">
Yes&nbsp;
<input type="radio" name="flgAdolescente" value="0" checked="checked">No</td> 
   </tr>
		  
		  
      <tr>
        <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="24%">Subjects' treatment time  </td>
        <td valign="top" class="TdNegroCuerposPq" width="24%">3&nbsp;
        day(s)</td>
       <td class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" width="26%">Subjects' follow up time </td>
        <td valign="top" class="TdNegroCuerposPq" width="26%">21&nbsp;  day(s)   </td>
      </tr>
	  <tr>
	  <td valign="top" align="justify" colspan="4">
	  <table cellpadding="1" cellspacing="0" border="1" width="100%" bgcolor="#FFFFFF" bordercolor="#E8E8F0"> 
		
		
	
		<tbody><tr>
	 
	   <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" colspan="3">Primary Outcome &nbsp;</td>
	  </tr><tr class="TdNegroCuerpoBoldPq" align="center"> 
 <td width="15%" bgcolor="#E8E8F0">Name of the outcome</td>
	  <td width="16%" bgcolor="#E8E8F0">Metric or method of measurement</td>
	  <td width="17%" bgcolor="#E8E8F0">Time point for the outcome</td>
	</tr>
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment </td> <td>Use of PCR for SARS-CoV-2. The primary outcome measure will be assessed using Fisher´s exact test. </td> <td width="17%">At day 7 post-treatment. &nbsp;</td>
		</tr>
	
		
		<tr>
	  
	  <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" colspan="3">Secondary Outcome  </td>
	  </tr> 
	<tr class="TdNegroCuerpoBoldPq" align="center"> 
 <td width="15%" bgcolor="#E8E8F0">Name of the outcome</td>
	  <td width="16%" bgcolor="#E8E8F0">Metric or method of measurement</td>
	  <td width="17%" bgcolor="#E8E8F0">Time point for the outcome</td>
	</tr>	
		
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Instestinal parasites by means of cuatitative kato-kats and Baerman. </td> <td>The study will use the burden and proportion of intestinal parasites.</td> <td width="17%">At day 1 and 14&nbsp;</td>
		</tr>
	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Viral load as
determined by PCR
cycle threshold (Ct). </td> <td>The mean viral load as
determined by PCR clycle
threshold (Ct) will be
used.
</td> <td width="17%">At baseline and on days 4,
7, 14, and 21 &nbsp;</td>
		</tr>
	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Patients with fever and cough </td> <td>The proportion of patients with fever an cough will be used.</td> <td width="17%">At days 4, 7, 14 and 21 post-treatment&nbsp;</td>
		</tr>
	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Patients with seroconversion </td> <td>The proportion of patients with seroconversion will be used
</td> <td width="17%">At day 21&nbsp;</td>
		</tr>
	
		
		<tr class="TdNegroCuerposPq" bgcolor="#FFFFFF"><td>Drug-related adverse events
 </td> <td>The study will use the proportion of drugrelated adverse events.</td> <td width="17%">During the entire study &nbsp;</td>
		</tr>
	
		
		</tbody></table></td></tr>
	  
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
       
				   <tr>
        <td class="TdBlancoCuerpoBoldPq" bgcolor="#6AB5FF" colspan="4" height="25">3. RESEARCH SITE, PRINCIPAL INVESTIGATOR, ETHICS COMMITTEE </td>
	  </tr>
<tr>
		<td colspan="4" bgcolor="#FFFFFF"><table cellpadding="0" cellspacing="0" border="1" bordercolor="#FFFFFF" bgcolor="#FFFFFF" width="100%">
		 <tbody><tr class="TdNegroCuerpoBoldPq" bgcolor="#FFFFFF">
		  <td bgcolor="#E8E8F0" colspan="3">Research site where the clinical trial will be conducted </td>
            <td bgcolor="#E8E8F0" width="13%">Principal Investigator </td>
			<td bgcolor="#E8E8F0" colspan="8">Institutional Research Ethics Committee (CIEI) that approved the trial for the site </td>
				  <td bgcolor="#E8E8F0" width="10%" rowspan="2">Observations</td>
		 </tr>
          <tr class="TdNegroCuerpoBoldPq" bgcolor="#FFFFFF">
		
            <td bgcolor="#E8E8F0" width="10%">Research Institution </td>
			<td width="5%" bgcolor="#E8E8F0">RCI</td>
			<td bgcolor="#E8E8F0" width="10%">Research site  </td>
			
			<td bgcolor="#E8E8F0" width="13%">Full name </td>
            <td bgcolor="#E8E8F0" width="5%">RCEI</td>
              <td bgcolor="#E8E8F0" width="7%">Ethics Committe Name  </td> 
			    <td bgcolor="#E8E8F0" width="7%">Status </td> 
              <td bgcolor="#E8E8F0" width="9%">Approval date</td>
			  <td bgcolor="#E8E8F0" width="10%">End approval date </td>
			    <td bgcolor="#E8E8F0" width="10%">Term </td>  <td bgcolor="#E8E8F0" width="9%">Telephone number</td>
			  <td bgcolor="#E8E8F0" width="10%">Email addrees </td>
			   
       </tr>
	  
	   <tr class="TdNegroCuerposPq">
         <td valign="top" width="10%" rowspan="3">HOSPITAL NACIONAL CAYETANO HEREDIA</td> 
         <td valign="top" rowspan="3">RCI 531  </td>
		<td valign="top" width="10%" rowspan="3">Investigación en Medicina Respiratoria<br><font style="color:#FF0000">
</font></td>
        
		<td valign="top" width="13%">PATRICIA JANNET GARCÍA FUNEGRA<br><br>

      
				</td>
		
		  <td valign="top" width="7%" rowspan="3">RCEI-305</td>
		<td valign="top" width="9%" rowspan="3">
		COMITÉ NACIONAL TRANSITORIO DE ÉTICA EN INVESTIGACIÓN PARA LA EVALUACIÓN Y SUPERVISIÓN DE ÉTICA DE LOS ENSAYOS CLÍNICOS DE LA ENFERMEDAD COVID-19&nbsp;-&nbsp;COMITÉ NACIONAL TRANSITORIO DE ÉTICA EN INVESTIGACIÓN PARA LA EVALUACIÓN Y SUPERVISIÓN DE ÉTICA DE LOS ENSAYOS CLÍNICOS DE LA ENFERMEDAD COVID-19</td><td valign="top" width="10%" align="center" rowspan="3">Approved</td>
		<td valign="top" width="10%" align="center" rowspan="3">09/07/2020</td>
		<td valign="top" width="12%" align="center" rowspan="3">09/07/2021</td><td valign="top" width="10%" align="center" rowspan="3">12</td><td valign="top" width="10%" align="center" rowspan="3">7126450 </td>
<td valign="top" width="10%" align="center" rowspan="3"></td>		
				<td width="6%" rowspan="3">
		

		- Clinical Trial Research Site Closure Resolución Directoral&nbsp;281-2020-OGITT-INS                                 with date 10/08/2020
		</td>
		</tr>
		<tr class="TdNegroCuerpoBoldPq">
		  <td class="TdNegroCuerposPq" bgcolor="#E8E8F0">Co-Investigator</td>
		</tr>
			<tr><td class="TdNegroCuerposPq">- German Javier Malaga Rodrìguez<br>- Patricia Hilda León Paredes<br>- César Ugarte Gil<br>- César Cárcamo Cavagnaro<br>- Hansel Kevin Mundaca Hurtado<br>- Carlos Chaccour Díaz<br> &nbsp;</td></tr>
			<tr>
			<td bgcolor="#E8E8F0" colspan="10" height="2"></td>
			</tr>
	 
		 <tr class="TdNegroCuerposPq">
		<td valign="top" rowspan="3">HOSPITAL NACIONAL CAYETANO HEREDIA		</td>
		 <td valign="top" rowspan="3">RCI-1188 		   </td>
		<td valign="top" rowspan="3">SERVICIO DE MEDICINA INTERNA 		<br><font style="color:#FF0000">
</font></td>
		
		<td valign="top" width="13%">PATRICIA JANNET GARCÍA FUNEGRA<br><br>


<br></td>
		
		 <td valign="top" width="7%" rowspan="3">RCEI-305&nbsp;</td>
		<td valign="top" width="9%" rowspan="3">COMITÉ NACIONAL TRANSITORIO DE ÉTICA EN INVESTIGACIÓN PARA LA EVALUACIÓN Y SUPERVISIÓN DE ÉTICA DE LOS ENSAYOS CLÍNICOS DE LA ENFERMEDAD COVID-19&nbsp;-&nbsp;COMITÉ NACIONAL TRANSITORIO DE ÉTICA EN INVESTIGACIÓN PARA LA EVALUACIÓN Y SUPERVISIÓN DE ÉTICA DE LOS ENSAYOS CLÍNICOS DE LA ENFERMEDAD COVID-19&nbsp;</td><td valign="top" width="10%" align="center" rowspan="3">Approved</td>
		<td valign="top" width="10%" align="center" rowspan="3">09/07/2020&nbsp;</td> 
		<td valign="top" width="12%" align="center" rowspan="3">09/07/2021&nbsp;</td><td valign="top" width="10%" align="center" rowspan="3"></td>
<td valign="top" width="10%" align="center" rowspan="3"></td>	
		<td valign="top" width="10%" align="center" rowspan="3">&nbsp;</td>
		
		<td class="TdNegroCuerposPq" rowspan="3">- Research Site Extension                                                                                                                             R.D.&nbsp;339-2020-OGITT-INS                                 with date 27/08/2020	&nbsp;</td>
		</tr><tr class="TdNegroCuerpoBoldPq">
		  <td class="TdNegroCuerposPq" bgcolor="#E8E8F0">Co-Investigator</td>
		</tr>
			<tr><td class="TdNegroCuerposPq"> &nbsp;</td></tr>
			<tr>
			<td bgcolor="#E8E8F0" colspan="13" height="5"></td>
			</tr>
	
		
		  </tbody></table></td>
		</tr> <tr><td colspan="4">
	  
		</td></tr>
	<tr>
	 <td class="TdNegroCuerpoBoldPq" width="25%" bgcolor="#E8E8F0" height="30">COMPLETION DATE:</td>
     <td valign="top" class="TdNegroCuerposPq" bgcolor="#FFFFFF" width="67%" colspan="3"> </td></tr>	
      </tbody></table></td>
	</tr>
	
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
    
<tr><td><table width="100%" border="0" cellpadding="0" cellspacing="1" bgcolor="#ffffff" bordercolor="#fffff">
	<tbody><tr>
        <td class="TdBlancoCuerpoBoldPq" bgcolor="#6AB5FF" colspan="4" height="25">4. IPD SHARING STATEMENT</td>
	  </tr> <tr valign="top">
	<td width="25%" rowspan="3" class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Is there a plan for sharing of deidentified individual clinical trial participant-level data (IPD)  to other researchers (including data dictionaries)?</td>
	
	<td width="70%" colspan="3" bgcolor="FFFFFF" class="TdNegroCuerposPq"><br>

	  
	  
	  <input type="radio" name="existe_plan" value="1">
	  Yes &nbsp;
	  <input type="radio" name="existe_plan" value="0" checked="checked">No
	    <input type="radio" name="existe_plan" value="2">
	    Non decided</td>
	</tr>

	<tr>
	<td class="TdNegroCuerpoBoldPq" height="22" bgcolor="#E8E8F0" colspan="3">In  case the answer is affirmative, describe the Plan.</td>
	</tr>
	<tr>
	<td bgcolor="FFFFFF" class="TdNegroCuerposPq" colspan="3">&nbsp;</td>
	</tr>
	
	<tr valign="middle">
	<td width="25%" rowspan="3" class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">Additional information that will be shared.</td>

	<td bgcolor="FFFFFF" class="TdNegroCuerposPq" colspan="3">
	 <input type="checkbox" name="inf_adicPE" value="1">
	 Study  protocol<br> 
	  
	  <input type="checkbox" name="inf_adicPAE" value="1">
	  Statistical  Analysis Plan<br>
	   
	 	  <input type="checkbox" name="inf_adicFCI" value="1">
	 	  Informed Consent Form<br> 
	
	  <input type="checkbox" name="inf_adicIEC" value="1">
	  Clinical  Study report<br> 
	 
	  <input type="checkbox" name="inf_adicO" value="1">
	  Others:

________________</td>
	</tr>
		<tr>
	<td class="TdNegroCuerpoBoldPq" height="22" bgcolor="#E8E8F0" colspan="3">Describe briefly when this information will be available and how it can be obtained </td>
	</tr>
	<tr>
	<td bgcolor="FFFFFF" class="TdNegroCuerposPq" colspan="3">&nbsp;<br></td>
	</tr><tr>
	<td width="25%" class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">URL</td>

	<td bgcolor="FFFFFF" class="TdNegroCuerposPq" colspan="3">
NA<br></td></tr>

	 </tbody></table></td></tr>
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
	   <tr>
	<td bgcolor="#ffffff" colspan="4">
	<table border="1" cellpadding="2" cellspacing="0" bordercolor="#E8E8F0" width="100%"><tbody><tr class="TdBlancoCuerpoBoldPq" bgcolor="#6AB5FF">
	<td class="TdBlancoCuerpoBoldPq" bgcolor="#6AB5FF" colspan="6" height="25">5. CLINICAL TRIAL CONTACT PERSONS INFORMATION </td>
	</tr><tr class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0" valign="top">
	<td width="30%" rowspan="2">Full Name </td>
	<td width="25%" rowspan="2">E-mail</td>
	<td width="10%" rowspan="2">Telephone</td>
	<td colspan="3" align="center">Type of queries to be resolved </td>
</tr>
	<tr class="TdNegroCuerpoBoldPq" bgcolor="#E8E8F0">
	<td align="center" width="15%">Information to general public </td>
	<td align="center" width="10%">Administrative Consultations </td>
	<td align="center" width="10%">Scientific Consultations </td>
	</tr>
 
	<tr bgcolor="#FFFFFF" class="TdNegroCuerposPq">
	<td>Patricia Jannet García  Funegra</td>
	<td>
	patricia.garcia@upch.pe	</td>
	<td>
	991886872                                         	</td>
	<td align="center"> 
	Yes	</td>
	<td align="center">
		</td>
	<td align="center">
	Yes	</td>
	</tr>
	
	<tr bgcolor="#FFFFFF" class="TdNegroCuerposPq">
	<td>Germán  Málaga  Rodríguez</td>
	<td>
	gmalaga01@gmail.com	</td>
	<td>
	992768300                                         	</td>
	<td align="center"> 
	Yes	</td>
	<td align="center">
		</td>
	<td align="center">
	Yes	</td>
	</tr>
	
	<tr bgcolor="#FFFFFF" class="TdNegroCuerposPq">
	<td>Hansel Kevin Mundaca Hurtado</td>
	<td>
	hansel.mundaca@upch.pe	</td>
	<td>
	950480633                                         	</td>
	<td align="center"> 
	Yes	</td>
	<td align="center">
	Yes	</td>
	<td align="center">
	Yes	</td>
	</tr>
	
	</tbody></table></td></tr>
	<tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
		<tr>
	<td valign="top" class="TdNegroCuerposPq">
	<table cellpadding="1" cellspacing="1" border="0" bgcolor="#FFFFFF" width="100%">
	<tbody><tr>
	 <td class="TdBlancoCuerpoBold" colspan="6" bgcolor="#6AB5FF">AUTHORIZATION STATUS</td>
	</tr>	
	<tr>
	
	  <td class="TdNegroCuerpoBoldPq" colspan="4"> 
		  AUTHORIZED  &nbsp;&nbsp;	  
		  ACTIVE
		</td>
	    
	</tr>
	
	<tr>
	  <td width="25%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">TYPE AND NUMBER OF 
	    AUTHORIZATION &nbsp; 
	    DOCUMENT </td>
	
	  <td width="22%" class="TdNegroCuerposPq" valign="top">R.D.&nbsp;
	238-2020-OGITT-INS</td>
    
	   <td width="23%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">AUTHRORIZATION &nbsp; 
	     DOCUMENT DATE (dd/mm/aaaa):
	   </td><td width="30%" class="TdNegroCuerposPq" valign="top">17/07/2020&nbsp;&nbsp;(Validity date from:17/07/2020)</td>
     </tr>
<tr>
	  <td width="25%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">SUMMARY EVALUATION REPORT</td>
	
	  <td colspan="3" class="TdNegroCuerposPq" valign="top"></td>
    
	   
     </tr>
	
	 <tr><td height="3" colspan="4"></td></tr>
	
		
		</tbody></table>
		</td>
		</tr>
	  <tr>
        <td width="25%" height="8" bgcolor="#ffffff" class="TdNegroCuerpoBoldPq" colspan="4"></td></tr>
	   <tr>
	   <td>
	   	<table cellpadding="0" cellspacing="0" border="1" width="100%" bordercolor="#FFFFFF">   
			<tbody><tr>
	  <td class="TdBlancoCuerpoBold" colspan="8" bgcolor="#6AB5FF">APPROVED PROCEDURES </td>

	  </tr>
	  <tr>
	    <td width="27%" rowspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">TYPE OF PROCEDURE </td>
          <td width="29%" rowspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">TYPE AND NUMBER OF RESOLUTION / OFFICIAL LETTER </td>  
          <td width="17%" rowspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">DATE OF RESOLUTION / OFFICIAL LETTER </td>
		    <td bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top" colspan="2">VALIDITY DATE </td>
		  
		     <td width="12%" rowspan="2" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">ANNULATION</td>
		  </tr><tr>
		     <td width="11%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top">FROM </td>
		     <td width="4%" bgcolor="#E8E8F0" class="TdNegroCuerpoBoldPq" valign="top"><p>TO</p>
            <p>&nbsp; </p></td>
		  </tr>
                  
                  <tr class="TdNegroCuerposPq">
                    <td valign="top" bgcolor="#D5F1FF">Clinical Trial Research Site Closure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                <br></td>   <td valign="top" bgcolor="#D5F1FF">R.D.&nbsp;281-2020-OGITT-INS                                <br></td>   <td valign="top" bgcolor="#D5F1FF">10/08/2020<br></td> <td valign="top" bgcolor="#D5F1FF"></td> <td valign="top" bgcolor="#D5F1FF"></td>
					<td valign="top" bgcolor="#D5F1FF"><br></td> 
                  </tr>
                  
                  <tr class="TdNegroCuerposPq">
                    <td valign="top" bgcolor="#D5F1FF">Research Site Extension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             <br></td>   <td valign="top" bgcolor="#D5F1FF">R.D.&nbsp;339-2020-OGITT-INS                                <br></td>   <td valign="top" bgcolor="#D5F1FF">27/08/2020<br></td> <td valign="top" bgcolor="#D5F1FF"></td> <td valign="top" bgcolor="#D5F1FF"></td>
					<td valign="top" bgcolor="#D5F1FF"><br></td> 
                  </tr>
                  
                  <tr class="TdNegroCuerposPq">
                    <td valign="top" bgcolor="#D5F1FF">Extension / Modification of Supply List                                                                                                                                                                                                                                                                                                                                                                                                                                                                             <br></td>   <td valign="top" bgcolor="#D5F1FF">R.D.&nbsp;485-2020-OGITT/INS                                <br></td>   <td valign="top" bgcolor="#D5F1FF">11/11/2020<br></td> <td valign="top" bgcolor="#D5F1FF"></td> <td valign="top" bgcolor="#D5F1FF"></td>
					<td valign="top" bgcolor="#D5F1FF"><br></td> 
                  </tr>
                  
              </tbody></table>
	   </td>
	   </tr>
	   

</tbody></table>
 	

	
		</td>
	 </tr>
	
	 </tbody></table>
	 </td>
	 </tr>
	
	 
	</tbody></table>	</td>
	</tr>
	 <tr> <td class="TdNegroCuerpoBoldPq" align="center"><input name="cerrar" value="Close" class="TdNegroCuerpoBoldPq" type="button" onclick="window.close()">
	 <input name="cerrar" value="Print" class="TdNegroCuerpoBoldPq" type="button" onclick="window.open(&#39;imprimirRecuperarECPBNuevo.asp?ver=EN&amp;numec=034-20&amp;flagH=&#39;,&#39;_self&#39;)">
	 </td>
	</tr>
	
</tbody></table>
</td></tr>
</tbody></table></td>
</tr>
</tbody></table>


</body><loom-container id="lo-engage-ext-container"><div></div><loom-shadow classname="resolved"></loom-shadow></loom-container></html>